Summary

Persistence Market Research has recently released a comprehensive report on the global Small Molecule CMO/CDMO Market. The report offers an in-depth analysis, highlighting key market drivers, trends, opportunities, and challenges, providing a thorough understanding of the market landscape.

Key Insights:

• Small Molecule CMO/CDMO Market Size (2024E): US$72.8 Bn
• Projected Market Value (2031F): US$104.5 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 4.1%

Scope of the Small Molecule CMO/CDMO Market Report:

The market covers a wide range of contract manufacturing and development services for small molecules, which are crucial components in pharmaceutical production. These services support treatments across diverse therapeutic areas such as oncology, cardiovascular, and central nervous system disorders. The market caters to biotech firms, pharmaceutical companies, and research institutions, driven by increasing demand for outsourcing pharmaceutical production, a rise in clinical trials, and advancements in small molecule drug research.

Key Market Growth Drivers:

The growth of the Small Molecule CMO/CDMO Market is propelled by rising demand for outsourcing drug development and manufacturing, offering cost-efficiency and scalability. Pharmaceutical companies increasingly depend on CDMOs to streamline operations, allowing them to focus on core activities like drug discovery and commercialization. Additionally, small molecule drugs' growing demand for various conditions, along with technological advancements like continuous manufacturing, further fuels market expansion.

Market Challenges:

Despite its growth potential, the market faces several challenges. Strict regulatory requirements, particularly Good Manufacturing Practices (GMP) compliance, increase operational costs. Additionally, intense competition and reliance on a few large contracts create pricing pressures, especially for smaller firms, impacting profitability.

Market Opportunities:

The growing complexity of drug molecules and the trend toward outsourcing R&D create numerous opportunities in the Small Molecule CMO/CDMO Market. Emerging markets, particularly in Asia-Pacific and Latin America, present significant growth potential due to lower production costs and skilled labor availability. Demand for high-potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs also opens lucrative opportunities for specialized service providers.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Small Molecule CMO/CDMO Market globally?
• How are technological advancements influencing the competitive landscape of the market?
• Who are the key players in the market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global Small Molecule CMO/CDMO Market?

Competitive Landscape and Business Strategies:

Leading players in the Small Molecule CMO/CDMO Market focus on innovation, expanding capacity, and forming strategic partnerships to maintain competitiveness. These companies invest significantly in R&D to develop advanced manufacturing techniques and offer comprehensive services. Collaborations with pharmaceutical, biotech firms, and research institutions are key strategies to secure long-term contracts and strengthen market positions.

Key Players Profiled:

• Pfizer CentreOne
• Baxter BioPharma Solutions
• Catalent
• Lonza
• Syngene International
• Boehringer Ingelheim
• Piramal Pharma Solutions
• Wuxi AppTec
• Patheon (Thermo Fisher Scientific Inc.)
• Adare Pharma Solutions

Market Segmentation:

By Product:

• Standard API
• HPAPI

By Service:

• Process Development
• Analytical Method Development
• GMP Manufacturing Service
• Scale-Up and Tech Transfer
• Quality Control and Quality Assurance
• Regulatory Assistance
• Technology and Innovation

By Company Size:

• Large
• Mid-sized
• Small

By Scale of Operation:

• Clinical
• Phase I
• Phase II
• Phase III
• Commercial

By Region:

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America







Persistence Market Research has recently released a comprehensive report on the global Small Molecule CMO/CDMO Market. The report offers an in-depth analysis, highlighting key market drivers, trends, opportunities, and challenges, providing a thorough understanding of the market landscape.

Key Insights:

• Small Molecule CMO/CDMO Market Size (2024E): US$72.8 Bn
• Projected Market Value (2031F): US$104.5 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 4.1%

Scope of the Small Molecule CMO/CDMO Market Report:

The market covers a wide range of contract manufacturing and development services for small molecules, which are crucial components in pharmaceutical production. These services support treatments across diverse therapeutic areas such as oncology, cardiovascular, and central nervous system disorders. The market caters to biotech firms, pharmaceutical companies, and research institutions, driven by increasing demand for outsourcing pharmaceutical production, a rise in clinical trials, and advancements in small molecule drug research.

Key Market Growth Drivers:

The growth of the Small Molecule CMO/CDMO Market is propelled by rising demand for outsourcing drug development and manufacturing, offering cost-efficiency and scalability. Pharmaceutical companies increasingly depend on CDMOs to streamline operations, allowing them to focus on core activities like drug discovery and commercialization. Additionally, small molecule drugs' growing demand for various conditions, along with technological advancements like continuous manufacturing, further fuels market expansion.

Market Challenges:

Despite its growth potential, the market faces several challenges. Strict regulatory requirements, particularly Good Manufacturing Practices (GMP) compliance, increase operational costs. Additionally, intense competition and reliance on a few large contracts create pricing pressures, especially for smaller firms, impacting profitability.

Market Opportunities:

The growing complexity of drug molecules and the trend toward outsourcing R&D create numerous opportunities in the Small Molecule CMO/CDMO Market. Emerging markets, particularly in Asia-Pacific and Latin America, present significant growth potential due to lower production costs and skilled labor availability. Demand for high-potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs also opens lucrative opportunities for specialized service providers.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Small Molecule CMO/CDMO Market globally?
• How are technological advancements influencing the competitive landscape of the market?
• Who are the key players in the market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global Small Molecule CMO/CDMO Market?

Competitive Landscape and Business Strategies:

Leading players in the Small Molecule CMO/CDMO Market focus on innovation, expanding capacity, and forming strategic partnerships to maintain competitiveness. These companies invest significantly in R&D to develop advanced manufacturing techniques and offer comprehensive services. Collaborations with pharmaceutical, biotech firms, and research institutions are key strategies to secure long-term contracts and strengthen market positions.

Key Players Profiled:

• Pfizer CentreOne
• Baxter BioPharma Solutions
• Catalent
• Lonza
• Syngene International
• Boehringer Ingelheim
• Piramal Pharma Solutions
• Wuxi AppTec
• Patheon (Thermo Fisher Scientific Inc.)
• Adare Pharma Solutions

Market Segmentation:

By Product:

• Standard API
• HPAPI

By Service:

• Process Development
• Analytical Method Development
• GMP Manufacturing Service
• Scale-Up and Tech Transfer
• Quality Control and Quality Assurance
• Regulatory Assistance
• Technology and Innovation

By Company Size:

• Large
• Mid-sized
• Small

By Scale of Operation:

• Clinical
• Phase I
• Phase II
• Phase III
• Commercial

By Region:

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Small Molecule CMO/CDMO Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Product Lifecycle Analysis
2.4. Small Molecule CMO/CDMO Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global Small Molecule CMO/CDMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Bn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2019-2023
3.2.2. Current Market Size Forecast, 2019-2023
3.3. Global Small Molecule CMO/CDMO Market Outlook: Product
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Product, 2019-2023
3.3.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Product, 2024-2031
3.3.3.1. Standard API
3.3.3.2. HPAPI
3.4. Market Attractiveness Analysis: Product
3.5. Global Small Molecule CMO/CDMO Market Outlook: Service
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Service, 2019-2023
3.5.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Service, 2024-2031
3.5.3.1. Process Development
3.5.3.2. Analytical Method Development
3.5.3.3. GMP Manufacturing Service
3.5.3.4. Scale-Up and Tech Transfer
3.5.3.5. Quality Control and Quality Assurance
3.5.3.6. Regulatory Assistance
3.5.3.7. Technology and Innovation
3.6. Market Attractiveness Analysis: Service
3.7. Global Small Molecule CMO/CDMO Market Outlook: Company Size
3.7.1. Introduction / Key Findings
3.7.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Company Size, 2019-2023
3.7.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Company Size, 2024-2031
3.7.3.1. Large
3.7.3.2. Mid-sized
3.7.3.3. Small
3.8. Market Attractiveness Analysis: Company Size
3.9. Global Small Molecule CMO/CDMO Market Outlook: Scale of Operation
3.9.1. Introduction / Key Findings
3.9.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Scale of Operation, 2019-2023
3.9.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Scale of Operation, 2024-2031
3.9.3.1. Clinical
3.9.3.2. Phase I
3.9.3.3. Phase II
3.9.3.4. Phase III
3.9.3.5. Commercial
3.10. Market Attractiveness Analysis: Scale of Operation
4. Global Small Molecule CMO/CDMO Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Region, 2019-2023
4.3. Current Market Size (US$ Bn) and Volume (Units) Forecast By Region, 2024-2031
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia & Pacific
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Small Molecule CMO/CDMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
5.3.1. By Country
5.3.2. By Product
5.3.3. By Service
5.3.4. By Company Size
5.3.5. By Scale of Operation
5.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024-2031
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Product, 2024-2031
5.5.1. Standard API
5.5.2. HPAPI
5.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Service, 2024-2031
5.6.1. Process Development
5.6.2. Analytical Method Development
5.6.3. GMP Manufacturing Service
5.6.4. Scale-Up and Tech Transfer
5.6.5. Quality Control and Quality Assurance
5.6.6. Regulatory Assistance
5.6.7. Technology and Innovation
5.7. Current Market Size (US$ Bn) and Volume (Units) Forecast By Company Size, 2024-2031
5.7.1. Large
5.7.2. Mid-sized
5.7.3. Small
5.8. Current Market Size (US$ Bn) and Volume (Units) Forecast By Scale of Operation, 2024-2031
5.8.1. Clinical
5.8.2. Phase I
5.8.3. Phase II
5.8.4. Phase III
5.8.5. Commercial
5.9. Market Attractiveness Analysis
6. Europe Small Molecule CMO/CDMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
6.3.1. By Country
6.3.2. By Product
6.3.3. By Service
6.3.4. By Company Size
6.3.5. By Scale of Operation
6.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024-2031
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Turkey
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Product, 2024-2031
6.5.1. Standard API
6.5.2. HPAPI
6.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Service, 2024-2031
6.6.1. Process Development
6.6.2. Analytical Method Development
6.6.3. GMP Manufacturing Service
6.6.4. Scale-Up and Tech Transfer
6.6.5. Quality Control and Quality Assurance
6.6.6. Regulatory Assistance
6.6.7. Technology and Innovation
6.7. Current Market Size (US$ Bn) and Volume (Units) Forecast By Company Size, 2024-2031
6.7.1. Large
6.7.2. Mid-sized
6.7.3. Small
6.8. Current Market Size (US$ Bn) and Volume (Units) Forecast By Scale of Operation, 2024-2031
6.8.1. Clinical
6.8.2. Phase I
6.8.3. Phase II
6.8.4. Phase III
6.8.5. Commercial
6.9. Market Attractiveness Analysis
7. East Asia Small Molecule CMO/CDMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
7.3.1. By Country
7.3.2. By Product
7.3.3. By Service
7.3.4. By Company Size
7.3.5. By Scale of Operation
7.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024-2031
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Product, 2024-2031
7.5.1. Standard API
7.5.2. HPAPI
7.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Service, 2024-2031
7.6.1. Process Development
7.6.2. Analytical Method Development
7.6.3. GMP Manufacturing Service
7.6.4. Scale-Up and Tech Transfer
7.6.5. Quality Control and Quality Assurance
7.6.6. Regulatory Assistance
7.6.7. Technology and Innovation
7.7. Current Market Size (US$ Bn) and Volume (Units) Forecast By Company Size, 2024-2031
7.7.1. Large
7.7.2. Mid-sized
7.7.3. Small
7.8. Current Market Size (US$ Bn) and Volume (Units) Forecast By Scale of Operation, 2024-2031
7.8.1. Clinical
7.8.2. Phase I
7.8.3. Phase II
7.8.4. Phase III
7.8.5. Commercial
7.9. Market Attractiveness Analysis
8. South Asia & Oceania Small Molecule CMO/CDMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
8.3.1. By Country
8.3.2. By Product
8.3.3. By Service
8.3.4. By Company Size
8.3.5. By Scale of Operation
8.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024-2031
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Product, 2024-2031
8.5.1. Standard API
8.5.2. HPAPI
8.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Service, 2024-2031
8.6.1. Process Development
8.6.2. Analytical Method Development
8.6.3. GMP Manufacturing Service
8.6.4. Scale-Up and Tech Transfer
8.6.5. Quality Control and Quality Assurance
8.6.6. Regulatory Assistance
8.6.7. Technology and Innovation
8.7. Current Market Size (US$ Bn) and Volume (Units) Forecast By Company Size, 2024-2031
8.7.1. Large
8.7.2. Mid-sized
8.7.3. Small
8.8. Current Market Size (US$ Bn) and Volume (Units) Forecast By Scale of Operation, 2024-2031
8.8.1. Clinical
8.8.2. Phase I
8.8.3. Phase II
8.8.4. Phase III
8.8.5. Commercial
8.9. Market Attractiveness Analysis
9. Latin America Small Molecule CMO/CDMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
9.3.1. By Country
9.3.2. By Product
9.3.3. By Service
9.3.4. By Company Size
9.3.5. By Scale of Operation
9.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024-2031
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Product, 2024-2031
9.5.1. Standard API
9.5.2. HPAPI
9.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Service, 2024-2031
9.6.1. Process Development
9.6.2. Analytical Method Development
9.6.3. GMP Manufacturing Service
9.6.4. Scale-Up and Tech Transfer
9.6.5. Quality Control and Quality Assurance
9.6.6. Regulatory Assistance
9.6.7. Technology and Innovation
9.7. Current Market Size (US$ Bn) and Volume (Units) Forecast By Company Size, 2024-2031
9.7.1. Large
9.7.2. Mid-sized
9.7.3. Small
9.8. Current Market Size (US$ Bn) and Volume (Units) Forecast By Scale of Operation, 2024-2031
9.8.1. Clinical
9.8.2. Phase I
9.8.3. Phase II
9.8.4. Phase III
9.8.5. Commercial
9.9. Market Attractiveness Analysis
10. Middle East & Africa Small Molecule CMO/CDMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis By Market, 2019-2023
10.3.1. By Country
10.3.2. By Product
10.3.3. By Service
10.3.4. By Company Size
10.3.5. By Scale of Operation
10.4. Current Market Size (US$ Bn) and Volume (Units) Forecast By Country, 2024-2031
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Bn) and Volume (Units) Forecast By Product, 2024-2031
10.5.1. Standard API
10.5.2. HPAPI
10.6. Current Market Size (US$ Bn) and Volume (Units) Forecast By Service, 2024-2031
10.6.1. Process Development
10.6.2. Analytical Method Development
10.6.3. GMP Manufacturing Service
10.6.4. Scale-Up and Tech Transfer
10.6.5. Quality Control and Quality Assurance
10.6.6. Regulatory Assistance
10.6.7. Technology and Innovation
10.7. Current Market Size (US$ Bn) and Volume (Units) Forecast By Company Size, 2024-2031
10.7.1. Large
10.7.2. Mid-sized
10.7.3. Small
10.8. Current Market Size (US$ Bn) and Volume (Units) Forecast By Scale of Operation, 2024-2031
10.8.1. Clinical
10.8.2. Phase I
10.8.3. Phase II
10.8.4. Phase III
10.8.5. Commercial
10.9. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2024
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition HPAPI
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Pfizer CentreOne
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Baxter BioPharma Solutions
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Catalent
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Lonza
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Syngene International
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Boehringer Ingelheim
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Piramal Pharma Solutions
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Wuxi AppTec
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Patheon (Thermo Fisher Scientific Inc.)
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Adare Pharma Solutions
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
11.3.11. Ajinomoto Bio-Pharma Services
11.3.11.1. Overview
11.3.11.2. Segments and Product
11.3.11.3. Key Financials
11.3.11.4. Market Developments
11.3.11.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations